SecBot SecBot

TLSA

Tiziana Life Sciences Ltd
Nasdaq· Pharmaceutical Preparations· Inc. D0· CIK 0001723069 Biotech & Drug Discovery
$0.9011 −0.05 (−5.15%)
Oct 26 4:00 PM ET · prev $0.9500
Market cap
$127.3M
Micro cap
Consensus
Buy
88% Buy or better · 8 analysts
Median target
🔒 Subscribers only
1 year
−52.3%
from $1.89 · Oct 27
30 days
−8.1%
from $0.9800
52-week range
$0.7700–1.95
−54% from high · low Sep 16
Avg volume 20D
583.8K
Oct 9 spike 2.42M
Short interest
2.64M
≈2.1% of shares · +52.3%
Days to cover
3.2
at average volume
Insider net
+$1.0M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Reddit crowd
40°
Cool · 1 mention this week
SecBot read MIXED 12 reports · 90 days
Balance 1 bearish · 4 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 8/12
Strongest BEARISH Tiziana Life Sciences reported H1 2026 interim results showing a deepened net loss of $12.4 million (vs…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.0M at an average $0.9988. No open-market sales. Price is 10% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 4 added (0 new), 1 trimmed or exited.

  • AnalystsBULLISH

    7 of 8 rate it Buy or better.

  • Short sellersBUILDING

    Short interest +52.3% to 2.64M shares. 3.2 days to cover, ≈2.1% of shares.

  • TrendRANGE

    12% below its 50-day average.

  • SocialQUIET

    Crowd 40° (cool) this week from 1 mention: 0 bullish, 1 bearish. No setup call.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GOLDMAN SACHS GROUP INCADD119,238$152.6K
CITADEL ADVISORS LLCDOUBLED80,222$102.7K
OSAIC HOLDINGS, INC.DOUBLED16,300$20.9K
JANE STREET GROUP, LLCTRIM13,794$17.7K
JONES FINANCIAL COMPANIES LLLPDOUBLED2,104$2.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

8 analysts
Buy 88% rate it Buy or better
Strong Buy3Buy4Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 22, 2026BTIG
REITERATE
REITERATEBuy
Sep 3, 2026BTIG
INITIATE
INITIATEBuy
Reddit
Crowd this week 40° Cool 0 bullish · 1 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent comments
r/wallstreetbets Bearish 3d ago
Today 100% of my gambling account is spread across: TSLQ (2X TSLA bear) TECS (3X tech industry bear) SOXS (3X SOX bear) I'm at breakeven (+0.2%) across all three right now. I think we'll see a dump at some point today. This week has been a very profitable one, shorting SPCX, TLSA, PLTR & AI players.
All social signals and their track records

Insider ledger

Form 4
$1.0M
bought · 2 insiders
$0
sold · 0 insiders
−9.8%
vs their $0.9988 cost
DateInsiderTypeValue
Aug 15, 2026
Elrifi Ivor
Chief Executive Officer
EXERCISE1,050,000 sh
Aug 5, 2026
Elrifi Ivor
Chief Executive Officer
BUY$237.6K
Aug 4, 2026
Elrifi Ivor
Chief Executive Officer
BUY$81.3K
Aug 3, 2026
Elrifi Ivor
Chief Executive Officer
BUY$667.0K
Jul 21, 2026
CERRONE GABRIELE M
Director
BUY$41.9K
Jul 21, 2026
CERRONE GABRIELE M
Director
AWARD$41.9K
Jun 12, 2026
CERRONE GABRIELE M
Director
BUY$16.6K
Jun 12, 2026
CERRONE GABRIELE M
Director
AWARD$16.6K

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.13-$0.14–-$0.12-8.0%$0.00
Next FY-$0.14-$0.14–-$0.14—$0.00

Short side

FINRA· Sep 30, 2026
2,640,735
shares short
+52.3%
vs prior settlement
3.2
days to cover
≈2.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Tiziana Life Sciences announced that management will attend the joint ACTRIMS-ECTRIMS meeting (MSToronto2026) in…
6-K — Impact 2/10
Oct 16, 2026 SEC
Tiziana Life Sciences reported H1 2026 interim results showing a deepened net loss of $12.4 million (vs. $5.3 million…
6-K — Impact 6/10
Oct 16, 2026 SEC
Tiziana Life Sciences announced that the last patient has begun dosing in its Phase 2 trial of intranasal foralumab…
6-K — Impact 4/10
Oct 16, 2026 Earnings result
TLSA Q2 2026 Earnings: EPS $-0.1 (-22.5% vs est)
Sep 17, 2026 Press
Tiziana Life Sciences signed a non-binding MOU with KAIMRC and the Foundation for Neurologic Diseases to collaborate…
Impact 4/10
Aug 15, 2026 Insider
Elrifi Ivor acquired via exercise 1,050,000 shares
Chief Executive Officer
Aug 5, 2026 Insider
Elrifi Ivor bought 237,616 shares
Chief Executive Officer @ $1.00 ($237.6K)
Aug 4, 2026 Insider
Elrifi Ivor bought 83,807 shares
Chief Executive Officer @ $0.9700 ($81.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 16, 2026
Earnings result
TLSA Q2 2026 Earnings: EPS $-0.1 (-22.5% vs est)
Sep 30, 2026
Short interest
Short Interest: TLSA up 52% to 2.6M shares
Settlement 2026-09-30 | Days to cover: 3.20 | ≈2.08% of shares outstanding (est.)
Sep 17, 2026
Contract
Tiziana Life Sciences Announces Signing of MOU with King Abdullah International Medical Research Center
BOSTON, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company…
Aug 24, 2026
FDA
Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026
BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company…
Jul 31, 2026
Short interest
Short Interest: TLSA up 37% to 1.7M shares
Settlement 2026-07-31 | Days to cover: 6.92 | ≈1.34% of shares outstanding (est.)

SecBot reports

21 filings · 4 press releases · 11 bullish · 1 bearish · 9 neutral
All TLSA filing & press-release reports (25)